Publications by authors named "Thomas M Cardillo"

Claim this Profile
T
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors.
Sara M Tolaney, Thomas M Cardillo, Chih-Chien Chou, Carrie Dornan, Mary Faris

Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer.
Jayakumar R Nair, Tzu-Ting Huang, Anu Sunkara, Margaret R Pruitt, Kristen R Ibanez, Thomas M Cardillo

iScience· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo.
Ian Nessler, Baron Rubahamya, Anna Kopp, Scott Hofsess, Thomas M Cardillo

Mol Cancer Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
Thomas M Cardillo, Maria B Zalath, Roberto Arrojo, Robert M Sharkey, Serengulam V Govindan

Oncotarget· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release.
Anna Kopp, Scott Hofsess, Thomas M Cardillo, Serengulam V Govindan, Jennifer Donnell

Mol Cancer Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Peptide Camptothecin Drug-linkers for Potent ADCs-Letter.
David M Goldenberg, Robert M Sharkey, Serengulam V Govindan, Thomas M Cardillo

Mol Cancer Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
Diana C DeLucia, Thomas M Cardillo, Lisa Ang, Mark P Labrecque, Ailin Zhang

Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.
Thomas M Cardillo, Diane L Rossi, Maria B Zalath, Donglin Liu, Roberto Arrojo

Oncotarget· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, Edmund A Rossi, Robert M Sharkey

Oncotarget· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130).
Robert M Sharkey, Serengulam V Govindan, Thomas M Cardillo, Jennifer Donnell, Jing Xia

Mol Cancer Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
Thomas M Cardillo, Serengulam V Govindan, Maria B Zalath, Diane L Rossi, Yang Wang

Mol Cancer Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
Chien-Hsing Chang, Yang Wang, Rongxiu Li, Diane L Rossi, Donglin Liu, Thomas M Cardillo

Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in -wild-type Triple-Negative Breast Cancer.
Thomas M Cardillo, Robert M Sharkey, Diane L Rossi, Roberto Arrojo, Ali A Mostafa

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Chien-Hsing Chang, Yang Wang, Maria Zalath, Donglin Liu, Thomas M Cardillo

Mol Cancer Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
Robert M Sharkey, William J McBride, Thomas M Cardillo, Serengulam V Govindan, Yang Wang

Clin Cancer Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, Edmund A Rossi, Robert M Sharkey

Oncotarget· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.
Serengulam V Govindan, Thomas M Cardillo, Edmund A Rossi, Preeti Trisal, William J McBride

Mol Pharm· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Thomas M Cardillo, Serengulam V Govindan, Robert M Sharkey, Preeti Trisal, Roberto Arrojo

Bioconjug Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
Diane L Rossi, Edmund A Rossi, Thomas M Cardillo, David M Goldenberg, Chien-Hsing Chang

MAbs· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.
Edmund A Rossi, Diane L Rossi, Thomas M Cardillo, Chien-Hsing Chang, David M Goldenberg

Mol Cancer Ther· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.
Donglin Liu, Thomas M Cardillo, Yang Wang, Edmund A Rossi, David M Goldenberg

Mol Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.
Donglin Liu, Chien-Hsing Chang, Edmund A Rossi, Thomas M Cardillo, David M Goldenberg

PLoS One· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Serengulam V Govindan, Thomas M Cardillo, Robert M Sharkey, Fatma Tat, David V Gold

Mol Cancer Ther· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.
Thomas M Cardillo, Preeti Trisal, Roberto Arrojo, David M Goldenberg, Chien-Hsing Chang

BMC Cancer· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties.
Edmund A Rossi, Chien-Hsing Chang, Thomas M Cardillo, David M Goldenberg

Bioconjug Chem· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis